{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:18:48Z","timestamp":1758759528153,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.semarthrit.2022.151973","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T05:09:53Z","timestamp":1643605793000},"page":"151973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures"],"prefix":"10.1016","volume":"53","author":[{"given":"Boyang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mianbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semarthrit.2022.151973_bib0001","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151973_bib0002","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.151973_bib0003","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard.60.12.1117","article-title":"Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale","volume":"60","author":"Geirsson","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151973_bib0004","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151973_bib0005","first-page":"186","article-title":"Disease activity indices in systemic sclerosis: a systematic literature review","volume":"34","author":"Melsens","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151973_bib0006","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2022.151973_bib0007","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.rmed.2016.09.011","article-title":"RISE-SSc: riociguat in diffuse cutaneous systemic sclerosis","volume":"122","author":"Distler","year":"2017","journal-title":"Respir Med"},{"issue":"150","key":"10.1016\/j.semarthrit.2022.151973_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0077-2018","article-title":"The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype","volume":"27","author":"Olson","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.151973_bib0009","first-page":"103","article-title":"Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia","volume":"30","author":"Song","year":"2013","journal-title":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG"},{"issue":"3 Suppl 29","key":"10.1016\/j.semarthrit.2022.151973_bib0010","first-page":"S42","article-title":"Assessment of disease severity and prognosis","volume":"21","author":"Medsger","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151973_bib0011","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00892-2018","article-title":"Mortality in interstitial lung disease: do race and skin colour matter?","volume":"51","author":"Morisset","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151973_bib0012","first-page":"995","article-title":"Anti-cyclic citrullinated peptide antibody, smoking, alcohol consumption, and disease duration as risk factors for extraarticular manifestations in Korean patients with rheumatoid arthritis","volume":"35","author":"Kim","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151973_bib0013","unstructured":"Zheng B, Wang M, McKenna K, Shapiro L, Silver R, Ellen Csuka M, et\u00a0al. Agreement between physician evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS). Arthritis Care Res (Hoboken).n\/a(n\/a)."},{"issue":"11","key":"10.1016\/j.semarthrit.2022.151973_bib0014","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151973_bib0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151973_bib0016","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/ard.2005.050187","article-title":"Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study","volume":"65","author":"Khanna","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.151973_bib0017","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","author":"Kafaja","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.151973_bib0018","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/rheumatology\/keh070","article-title":"Scleroderma Trials Study G. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma","volume":"43","author":"Sultan","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151973_bib0019","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard.62.9.901","article-title":"European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria","volume":"62","author":"Valentini","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.151973_bib0020","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.62.9.904","article-title":"European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score","volume":"62","author":"Valentini","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.151973_bib0021","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/annrheumdis-2018-214764","article-title":"Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis","volume":"78","author":"Ferdowsi","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.151973_bib0022","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3899\/jrheum.151440","article-title":"Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician\u2019s Global Assessment of Disease Severity in Systemic Sclerosis","volume":"43","author":"Harel","year":"2016","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.151973_bib0023","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151973_bib0024","first-page":"148","article-title":"Assessment of sensitivity to change of the European Scleroderma Study Group activity index","volume":"34","author":"Melsens","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.151973_bib0025","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/rheumatology\/kex015","article-title":"Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort","volume":"56","author":"Nevskaya","year":"2017","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.151973_bib0026","first-page":"832","article-title":"Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial","volume":"32","author":"Khanna","year":"2005","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.151973_bib0027","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3899\/jrheum.090375","article-title":"The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma","volume":"37","author":"Sekhon","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.151973_bib0028","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:07:53Z","timestamp":1758733673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":28,"alternative-id":["S0049017222000245"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151973","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151973"}}